Z Philips

2.5k total citations · 1 hit paper
48 papers, 1.9k citations indexed

About

Z Philips is a scholar working on Economics and Econometrics, Oncology and Epidemiology. According to data from OpenAlex, Z Philips has authored 48 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Economics and Econometrics, 16 papers in Oncology and 16 papers in Epidemiology. Recurrent topics in Z Philips's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Cervical Cancer and HPV Research (14 papers) and Global Cancer Incidence and Screening (12 papers). Z Philips is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Cervical Cancer and HPV Research (14 papers) and Global Cancer Incidence and Screening (12 papers). Z Philips collaborates with scholars based in United Kingdom, Canada and Ireland. Z Philips's co-authors include Karl Claxton, Mark Sculpher, Laura Ginnelly, Stephen Palmer, Su Golder, David K. Whynes, Julie Glanville, R.P. Riemsma, Mark Avis and John Posnett and has published in prestigious journals such as British Journal of Cancer, Human Reproduction and European Journal of Cancer.

In The Last Decade

Z Philips

47 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Review of guidelines for good practice in decision-analytic modelling in health technology assessment

2004 528 citations Z Philips, Laura Ginnelly et al. Health Technology Assessment profile →

Peers

Countries citing papers authored by Z Philips

Since Specialization

Citations

This map shows the geographic impact of Z Philips's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Z Philips with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Z Philips more than expected).

Fields of papers citing papers by Z Philips

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Z Philips. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Z Philips. The network helps show where Z Philips may publish in the future.

Co-authorship network of co-authors of Z Philips

This figure shows the co-authorship network connecting the top 25 collaborators of Z Philips. A scholar is included among the top collaborators of Z Philips based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Z Philips. Z Philips is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation 2023 ·PharmacoEconomics ·Péter Gál, (unknown), (unknown), Ray Gani, (unknown), Ash Bullement, Z Philips, (unknown)	1
2	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England 2018 ·The European Journal of Health Economics ·Yang Meng, (unknown), (unknown), (unknown), Helen M. Johnson, Z Philips, Neil Roskell, Andrew Walker, Dawn Lee	20
3	Variation In Health Technology Assessment And Reimbursement Decisions In England, France, And Germany: Spotlight On The Impact Of Uncertainty 2017 ·Value in Health ·(unknown), (unknown), Z Philips, Ron Akehurst	1
4	Cost Effectiveness of Nivolumab Monotherapy for the Treatment of Advanced Melanoma Patients in the United Kingdom 2016 ·Value in Health ·Yang Meng, (unknown), (unknown), Helen M. Johnson, Z Philips, Neil Roskell, Dawn Lee	1
5	Management of low‐grade cervical abnormalities detected at screening: which method do women prefer? 2008 ·Cytopathology ·D K Whynes, Claire Woolley, Z Philips, (unknown)	12
6	Prenatal screening and treatment strategies to prevent group B streptococcal and other bacterial infections in early infancy: cost-effectiveness and expected value of information analyses 2007 ·Health Technology Assessment ·Tim Colbourn, Christian Asseburg, Laura Bojke, Z Philips, Karl Claxton, A. E. Ades, Ruth Gilbert	58
7	United Kingdom cervical cancer screening and the costs of time and travel 2007 ·International Journal of Technology Assessment in Health Care ·Claire Woolley, Z Philips, David K. Whynes, Seonaidh Cotton, Nicola Gray, Linda Sharp, Julian Little, Norman Waugh, (unknown)	11
8	Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses 2007 ·BMJ ·Tim Colbourn, Christian Asseburg, Laura Bojke, Z Philips, Nicky J. Welton, Karl Claxton, A. E. Ades, Ruth Gilbert	41
9	Introducing HPV Triage into the English Cervical Cancer Screening Program: Consequences for Participation 2006 ·Women & Health ·Z Philips, Mark Avis, David K. Whynes	13
10	Trial of management of borderline and other low-grade abnormal smears (TOMBOLA): Trial design 2006 ·Contemporary Clinical Trials ·Seonaidh Cotton, Linda Sharp, Julian Little, Ian D. Duncan, (unknown), Margaret Cruickshank, Nicola Gray, David Jenkins, Z Philips, Alistair Robertson, Rashmi Seth	44
11	Refining the Management of Low-Grade Cervical Abnormalities in the UK National Health Service and Defining the Potential for Human Papillomavirus Testing: A Commentary on Emerging Evidence 2005 ·Journal of Lower Genital Tract Disease ·Elaine Bentley, Seonaidh Cotton, Margaret Cruickshank, Ian D. Duncan, Nicola Gray, David Jenkins, Julian Little, Keith Neal, Z Philips, Ian Russell, Rashmi Seth, Linda Sharp, Norman Waugh	14
12	Developing a questionnaire to measure the psychosocial impact of an abnormal cervical smear result and its subsequent management: the TOMBOLA (Trial Of Management of Borderline and Other Low-grade Abnormal smears) trial 2005 ·Quality of Life Research ·Nicola Gray, Linda Sharp, Seonaidh Cotton, Mark Avis, Z Philips, Ian Russell, Liz Walker, David K. Whynes, Julian Little	40
13	Review of guidelines for good practice in decision-analytic modelling in health technology assessment breakdown → 2004 ·Health Technology Assessment ·Z Philips, Laura Ginnelly, Mark Sculpher, Karl Claxton, Su Golder, R.P. Riemsma, (unknown), Julie Glanville	528
14	A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme 2004 ·Health Technology Assessment ·Karl Claxton, Laura Ginnelly, Mark Sculpher, Z Philips, Stephen Palmer	212
15	An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme 2004 ·British Journal of Cancer ·Chris Sherlaw‐Johnson, Z Philips	55
16	Pharmaceutical care for elderly patients shared between community pharmacists and general practitioners: a randomised evaluation. RESPECT (Randomised Evaluation of Shared Prescribing for Elderly people in the Community over Time) [ISRCTN16932128] 2004 ·BMC Health Services Research ·Ian Chi Kei Wong, P. Campion, Simon Coulton, Ben Cross, (unknown), Amanda Farrin, Graham Hill, Andrea Hilton, Z Philips, Stewart Richmond, Ian Russell	16
17	Design of a Prospective Economic Evaluation for a Tri-National Clinical Trial in HIV Patients (OPTIMA) 2003 ·Controlled Clinical Trials ·Julie Munakata, John Woolcott, Aslam H. Anis, (unknown), Wei Yu, Gillian D Sanders, (unknown), Vilija R. Joyce, (unknown), Z Philips, Douglas K Owens	1
18	Psychosocial and economic aspects of a trial of management of mild and borderline cervical abnormalities (TOMBOLA) 2002 ·European Journal of Oncology Nursing ·Z Philips, Nicola Gray, Mark Avis, David K. Whynes	7
19	Early withdrawal from cervical cancer screening: the question of cost-effectiveness 2001 ·European Journal of Cancer ·Z Philips, David K. Whynes	7
20	Deriving a compound quality of life measure from the EORTC-QLQ-C30/LC13 instrument for use in economic evaluations of lung cancer clinical trials 2001 ·European Journal of Cancer ·A Bagust, (unknown), Z Philips	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact